Sugi Predict

Sugi Predict / Targets / CLSPN

CLSPN

Claspin · Q9HAW4 · CLSPN on Sugi Atlas →

0 patent compounds predicted against CLSPN, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CLSPN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer PHASE3COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
Effects of Cannabidiol (CBD) on the Activation of Autophagy and Inflammation Genes, Functional Consequences in Virologically Controlled HIV-infected Patients PHASE2COMPLETED
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis PHASE2COMPLETED
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors PHASE1COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis PHASE1COMPLETED
PCD New Gene Discovery nanCOMPLETED
Diagnosis of Primary Ciliary Dyskinesia nanCOMPLETED
Observational Study of Blood Treated With Cytolin nanCOMPLETED
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease nanRECRUITING
Molecular and Genetic Studies of Congenital Myopathies nanRECRUITING
The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH) nanCOMPLETED
Identification of New FTLD Genes nanUNKNOWN
Genetics of Primary Ciliary Dyskinesia nanCOMPLETED
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) nanCOMPLETED
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Immune Cell Response to Stimuli nanRECRUITING
Immunogenetics of Visceral Leishmaniasis nanCOMPLETED
Genetic Variants in Linear Localized Scleroderma nanCOMPLETED
Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s) nanCOMPLETED
Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA nanRECRUITING
Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects nanWITHDRAWN
Blood-based Biomarkers for the Prognosis of Sports Related Concussion nanCOMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. nanUNKNOWN
Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate nanRECRUITING
Clinically Actionable Tumor-Associated Antigens in Prostate Cancer nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CLSPN binder may also engage these)

ProteinNameSimilarity
Q80YR7 — 1.000 Q80YR7 →
Q76FK4 — 0.994 Q76FK4 →
Q6GNV6 — 0.994 Q6GNV6 →
Q9DF50 — 0.993 Q9DF50 →
Q58EL7 — 0.991 Q58EL7 →
Q5FBB7 — 0.991 Q5FBB7 →
A6QLA6 — 0.991 A6QLA6 →
Q4KLH6 — 0.990 Q4KLH6 →
Q9ERH4 — 0.990 Q9ERH4 →
Q6ZQ06 — 0.990 Q6ZQ06 →
Q99708 — 0.990 Q99708 →
Q3UHX0 — 0.990 Q3UHX0 →
Q5TB80 — 0.989 Q5TB80 →
A0JM80 — 0.989 A0JM80 →
Q15398 — 0.989 Q15398 →
Q3T8J9 — 0.988 Q3T8J9 →
Q5W0B1 — 0.988 Q5W0B1 →
Q6DJL7 — 0.988 Q6DJL7 →
Q5RD97 — 0.988 Q5RD97 →
A6H5Y1 — 0.988 A6H5Y1 →
B1H1S4 — 0.988 B1H1S4 →
Q8K4R9 — 0.988 Q8K4R9 →
Q8C263 — 0.987 Q8C263 →
Q80YR6 — 0.987 Q80YR6 →
Q6P0N0 — 0.987 Q6P0N0 →
A9C3N6 — 0.987 A9C3N6 →
B2GUZ2 — 0.987 B2GUZ2 →
A1L2Y1 — 0.987 A1L2Y1 →
Q8RWK8 — 0.987 Q8RWK8 →
Q5REF4 — 0.987 Q5REF4 →